Why not bapineuzumab?
Like Aduhelm this long-discontinued amyloid beta MAb reduced brain beta amyloid; so have several other industry projects.
Fortunes diverge for solo drug launchers
A solo drug launch is a testing time for a small company, made even tougher by the pandemic.
Recycling pays off for Mereo
The company has spent five years buying in discontinued projects, and at last has managed to sell one of these on at a nice profit.
Mapping the transatlantic divide for biotech flotations
A look at how drug developers fare after floating in Europe suggests why many tread a path to the US and a Nasdaq listing.
Curevac rides the Covid wave
Curevac’s market cap has ballooned almost fivefold since floating, sending the mRNA company into the record books.
Biogen pays $560m for an unproven Parkinson’s mechanism
All the attention is on aducanumab, but yesterday’s deal with Denali is a reminder that Biogen has other irons in the fire.
